Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Chronic radiation proctitis (CRP) is the main secondary toxic injury after pelvic
radiotherapy. Hematochezia is the most common symptom for more than 80% of CRP patients.
Non-surgical treatment is the first choice to the treatment of CRP to avoid the occurrence of
serious complications. Conventional oral medication for the treatment of bleeding CRP is very
few and has little effect. At present, no oral medication has been found to significantly
alleviate and control refractory bleeding of CRP. Therefore, it is an urgent problem to
screen out a drug that is more effective, safe and highly compliant for the treatment of
hemorrhagic CRP.
Thalidomide has anti-inflammatory, immune regulation, anti-angiogenesis and other effects.
For the patients of CRP with intractable bleeding, a prospective, open clinical trial will be
carried out to observe the safety and effectiveness of thalidomide in treating hemorrhagic
CRP.